Jul 31 2023 |
UCB, Inc. v. Actavis Laboratories UT, Inc. No. 2021-1924, (Fed. Cir. Apr. 12, 2023) |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 31 2023 |
Proposed Class Action Dismissed Over Lack of Standing |
Keller and Heckman LLP |
Jul 31 2023 |
The 2024 Proposed Hospital Outpatient Prospective Payment System and Physician Fee Schedule Rules: What Pharma Stakeholders Need to Know |
ArentFox Schiff LLP |
Jul 31 2023 |
Bipartisan Group of Representatives Calls on EPA to Assess the Risks of PFAS in Fluorinated Containers |
Bergeson & Campbell, P.C. |
Jul 31 2023 |
APHIS 2022 Impact Report Includes Summary of Biotechnology Activities |
Bergeson & Campbell, P.C. |
Jul 28 2023 |
Will Mississippi’s List of Qualifying Conditions for Medical Cannabis Soon Be Expanded? |
Bradley Arant Boult Cummings LLP |
Jul 28 2023 |
Amendment to House Bill Threatens Funding of Organic Standards |
Keller and Heckman LLP |
Jul 27 2023 |
CMS Proposes Changes to Medicare Provider Enrollment Rules |
Polsinelli PC |
Jul 27 2023 |
New Medicare Marketing Definition |
Squire Patton Boggs (US) LLP |
Jul 27 2023 |
CMS Proposes Remedy for 340B-Acquired Drug Payment Policy for CY 2018-2022 |
Foley & Lardner LLP |
Jul 27 2023 |
FDA Maintains Focus on “Intended Use” for Software-Enabled Medical Devices |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 27 2023 |
FDA Denies Request to Reconsider Petition on Phthalates in Food Packaging |
Keller and Heckman LLP |
Jul 26 2023 |
Bipartisan Legislation Would Strengthen USDA’s BioPreferred Program |
Bergeson & Campbell, P.C. |
Jul 26 2023 |
July 2023 EU’s New HBER and Horizontal Guidelines: Main Changes |
Greenberg Traurig, LLP |
Jul 25 2023 |
First Nonprescription Birth Control Pill Approved for Marketing by FDA: A Milestone for Reproductive Health |
Mintz |
Jul 25 2023 |
The Netherlands Provides Taste Testing of Cell-Cultivated Meat and Seafood |
Keller and Heckman LLP |
Jul 25 2023 |
Real Estate Beneficial Ownership Regulatory Alert: Complying with Foreign Ownership Reporting Requirements in US Real Estate |
K&L Gates |
Jul 25 2023 |
Big Tobacco Bets Big On Cannabis |
Bradley Arant Boult Cummings LLP |
Jul 25 2023 |
Washington State’s Aggressive Approach to Preventing Intoxicating Hemp Cannabinoids May Be Adopted in Other States |
Wilson Elser Moskowitz Edelman & Dicker LLP |
Jul 24 2023 |
Regulators Send Warning Letter to Hospitals and Telehealth Providers About Tracking Technology Use |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 21 2023 |
EPA Extends Comment Period on Proposed SNURs for 18 Chemicals Made from Plastic Waste-Based Feedstocks |
Bergeson & Campbell, P.C. |
Jul 21 2023 |
Reintroduced Bill Seeks Legal Pathway for CBD in Food |
Keller and Heckman LLP |
Jul 21 2023 |
Post-Dobbs Hospital Risk Assessment, Part 2: Impacts Beyond Abortion |
ArentFox Schiff LLP |
Jul 20 2023 |
Changing Landscape: Federal and State Regulators Focus on Protecting Consumer Health Data |
Foley & Lardner LLP |
Jul 20 2023 |
U.S. Executive Branch Update – July 20, 2023 |
Squire Patton Boggs (US) LLP |
Jul 20 2023 |
Lab Study Shows Oral Antacid Drug Performs Differently When Mixed with Various Food Vehicles |
Keller and Heckman LLP |
Jul 19 2023 |
EPA Announces Release of Guidance for the Evaluation of Products for Claims against Viruses |
Bergeson & Campbell, P.C. |
Jul 19 2023 |
USDA FSIS Implements Directives to Inspection Program Personnel as Cell-Cultured Meats Begin to Enter the U.S. Market. |
Keller and Heckman LLP |
Jul 19 2023 |
Trending in Telehealth: June 27 – July 10, 2023 |
McDermott Will & Emery |
Jul 19 2023 |
IP Toolbox Is Crucial In AI-Powered Drug Discovery |
Foley & Lardner LLP |
Jul 18 2023 |
Complex Healthcare Litigation Toolkit: The Use of Plaintiff Fact Sheets and Summary Jury Trials |
Foley & Lardner LLP |
Jul 18 2023 |
U.S. Executive Branch Update – July 18, 2023 |
Squire Patton Boggs (US) LLP |
Jul 18 2023 |
EPA Extends Comment Period on Proposed Updates to TSCA New Chemicals Regulations; Comments Due August 8, 2023 |
Bergeson & Campbell, P.C. |
Jul 18 2023 |
Hospital Price Transparency Changes in the Calendar Year 2024 Hospital Outpatient Prospective Payment System Proposed Rule |
Nelson Mullins |
Jul 18 2023 |
District of Columbia Employers Take Notice: City’s Cannabis Employment Protections Amendments Act Takes Effect |
ArentFox Schiff LLP |
Jul 18 2023 |
Report: Digital Health in India in 2023 |
Nishith Desai Associates |
Jul 18 2023 |
This Week in 340B: July 6 – 17, 2023 |
McDermott Will & Emery |
Jul 18 2023 |
Those Aren’t Doritos: FTC and FDA Send Warning Letters to Companies Marketing Delta-8 Infused Munchies |
Mintz |
Jul 18 2023 |
Montana Enacts Genetic Information Privacy Law |
Jackson Lewis P.C. |
Jul 17 2023 |
California Assembly Passes Bill that Would Prohibit Certain Food Additives |
Greenberg Traurig, LLP |
Jul 17 2023 |
In a Landmark Decision, China’s Supreme Court Reverses Lower Court Decision Banning Excessively High Prices on a Patent-Protected Pharmaceutical Product |
Greenberg Traurig, LLP |
Jul 17 2023 |
Healthcare Preview for The Week Of: July 17, 2023 |
McDermott Will & Emery |
Jul 17 2023 |
Petition Filed to Add Methyl Ethyl Ketoxime to List of Chemical Substances Subject to Superfund Excise Tax |
Bergeson & Campbell, P.C. |
Jul 17 2023 |
SEC Cannabis Enforcement Continuing to Grow this Past Spring |
Foley & Lardner LLP |
Jul 17 2023 |
FDA Extends Enforcement Discretion Policies in FSMA Guidances Involving Onsite Visits Abroad Due to the Ongoing, International Impact of COVID-19 |
Keller and Heckman LLP |
Jul 17 2023 |
Key Takeaways from the FDA’s First Draft Guidance on Clinical Trials with Psychedelic Drugs |
Foley & Lardner LLP |
Jul 14 2023 |
Navigating the Pricing Regulation for Pharmaceuticals and Medical Devices in India – Part B [Podcast] |
Nishith Desai Associates |
Jul 14 2023 |
Navigating the Pricing Regulation for Pharmaceuticals and Medical Devices in India – Part A |
Nishith Desai Associates |
Jul 14 2023 |
FDA Releases Final Guidance on Quantitative Efficacy and Risk Information in Direct-to-Consumer Promotional Labeling and Advertisements |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 14 2023 |
CMS Releases Proposed Remedy for 340 B-Acquired Drugs Purchased in Cys 2018–2022 |
McDermott Will & Emery |